1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  

This page is powered by Blogger. Isn't yours?

Thursday, March 30, 2017

 

Could flashing light treat Alzheimer’s? Fresh approaches to treating the disease: VIDEO


























Alzheimer's disease is one of the biggest unanswered questions in medicine.

Five million Americans are currently estimated to have the mind-ravaging disease, a number expected to triple by 2050 without effective interventions. But the track record in drug development has been terrible: a success rate of less than 1 percent.

"Already 1 of $5 of Medicare and Medicaid goes to Alzheimer's," said Rudy Tanzi, director of the genetics and aging research unit at Massachusetts General Hospital and a professor of neurology at Harvard Medical School. "As 71 million Baby Boomers like I head toward risk age, it will go into 1 of $3 or 1 of $2, and Alzheimer's will single-handedly collapse our health-care system. It will single-handedly collapse Medicare and Medicaid in this country."

The need for treatments stands in stark contrast to science's understanding of the disease. With each major clinical trial failure — there have been at least eight in the last decade, most recently Eli Lilly's, in November, and Merck's, in February — the field questions whether researchers are even focusing on the right thing. Specifically: the amyloid plaques clogging the brain that are hallmarks of Alzheimer's.

"The idea has been tested and shown to be incorrect," said George Perry, professor and dean of the College of Sciences at the University of Texas at San Antonio. "On a rational basis there's no reason to continue with this hypothesis."

Perry is in the minority. Researchers like Harvard's Tanzi are convinced by genetic data that amyloid is the right target, saying patients just need to be treated earlier in the disease, before it's started robbing them of memory and cognition.

"Any scientist who's been reading the literature carefully and paying attention to all the details for the last 30 years of the journey of the amyloid hypothesis would have to come to only one conclusion, and that is that the trials have failed the hypothesis," Tanzi said in an interview in his office in Boston.

And despite the failure rate, the leading trials in Alzheimer's disease are still targeting amyloid — but earlier in the disease's course. Biogen is spending more than $2 billion to answer this question in late-stage clinical studies.

But because of the controversy, it's refreshing to see alternative ideas, however early in development. There's the approach of young biotech Voyager Therapeutics, using the viral delivery systems of gene therapy to penetrate the blood-brain barrier, what some have described as a sort of screen door between the body and the brain, to create proteins in brain cells to affect the disease.

"The cool thing about this approach is that because the vector gets into brain cells, neurons or glia, it sets up shop and with a single injection we can produce antibody for many, many years," said Voyager CEO Dr. Steve Paul.

Paul spent years at Lilly and subscribes to the amyloid hypothesis, though a main focus of Voyager's Alzheimer's program is another important protein, tau. It's still a few years from testing in humans.

Another early approach is even more radical: the idea that we could treat Alzheimer's with light.

In a paper published in the journal Nature in December, researchers at MIT led by Dr. Li-Huei Tsai found that light entrainment cleared plaques from the brains of mice. The idea focuses on a brainwave frequency known as gamma.

"Gamma rhythms are known to be involved in higher-order brain functions, like perception, attention, and the formation of working memory," Tsai said from her lab at MIT's Picower Institute for Learning and Memory in Cambridge, Massachusetts.

Those rhythms — neurons firing synchronously in the brain — have been found to be impaired in people with Alzheimer's, Tsai explained. So she set out to see what would happen if they could be restored.

She decided to use a flashing light to aim to restore the rhythms — an idea she says she got after seeing research from the late 1980s in cats. And sure enough, by rigging LED lights to flash at the gamma frequency — 40 times per second — her team found gamma rhythms were restored in the brains of mice.

"We were delighted," Tsai said.

So then the question of what happens when those rhythms come back in an Alzheimer's disease brain.

"It was unbelievable," Tsai recalled. "At first we were very surprised to see that after we induced gamma rhythms in the Alzheimer's model, the amyloid is greatly reduced. Within just one hour, we saw the amyloid level was cut almost by half."

There were other signs of good news in the brain, too: an effect on tau and inflammation, also implicated in Alzheimer's, plus a restoring of the function of microglia — what Tsai described as the brain's janitors — against amyloid.

So does this mean all it takes to treat Alzheimer's is for people to sit in a room for an hour a day with LED lights flashing at 40 times per second? Not so fast, Tsai said. Though she said there has been a lot of excitement around the work.

"Since the paper was published in December last year I literally have been bombarded by emails and phone calls," Tsai said. "Because the approach is so easy and non-invasive, many people want to know how to apply it to human subjects. I think we still really need to know whether there is any adverse effect after long-term treatment."

A startup company, Cognito Therapeutics, has licensed the technology from MIT to advance potential treatments into human testing. Tsai cautioned there is still a ways to go.

Story Source: The above story is based on materials provided by CNBC
Note: Materials may be edited for content and length

Labels: